Tafamidis Meglumine

Vyndaqel

NADAC/unit N/A

No Shortage

Covered Lives

Active Shortages

2025-09-29 Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025., Pfizer Inc.

Explore in the Ecosystem

rxsaver.aiCompare prices for Tafamidis Meglumine drfinder.aiFind doctors who prescribe Tafamidis Meglumine rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Tafamidis Meglumine

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.